Items Tagged ‘brca’

November 9th, 2016

Lynparza™ Clinical Trial Demonstrates Survival Benefit in Relapsed Ovarian Cancer

By

AstraZeneca has announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LynparzaTM (olaparib) oral therapy for the maintenance treatment of platinum-sensitive relapsed, BRCA-mutated ovarian cancer.1 Results from the trial demonstrate a clinically-meaningful improvement in survival free of cancer progression. Importantly, the median time to cancer progression for Lynparza-treated patients […]

View full entry

Tags: AstraZeneca, BRACAnalysis CDx, brca, lynparza, News, olaprarib, Ovarian Cancer, PARP enzyme, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer


December 29th, 2014

Lynparza Approved in Advanced Ovarian Cancer

By

CancerConnect News: The U.S. Food and Drug Administration has granted accelerated approval to LynparzaTM (olaparib), a new drug treatment for women with advanced ovarian cancer associated with defective BRCA genes. According to statistics from the American Cancer Society (ACS), ovarian cancer causes more deaths than any other cancer of the female reproductive system. The ACS […]

View full entry

Tags: brca, lynparza, News, olaparib, Ovarian Cancer, parp, Recurrent Ovarian Cancer, Stage II-IV Ovarian Cancer